Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Digestive System Neoplasms|Endocrine Gland Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Breast Diseases|Renal Neoplasm|Solid Tumors
Interventions: DRUG: Entinostat|DRUG: Pembrolizumab
Sponsor: Syndax Pharmaceuticals
Collaborators: Merck Sharp & Dohme LLC